These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19245087)

  • 1. Antiplatelet agents for prevention of recurrent ischemic stroke.
    Hegge KA
    S D Med; 2009 Jan; 62(1):15-7. PubMed ID: 19245087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
    Hankey GJ
    Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
    Burke JP; Sander S; Shah H; Zarotsky V; Henk H
    Curr Med Res Opin; 2010 May; 26(5):1023-30. PubMed ID: 20199138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
    Hankey GJ; Eikelboom JW
    Neurology; 2005 Apr; 64(7):1117-21. PubMed ID: 15824331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
    Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC
    Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelets and stroke outcomes: state of the science.
    Meyer D
    Crit Care Nurs Clin North Am; 2009 Dec; 21(4):517-28. PubMed ID: 19951767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet drugs for ischemic stroke prevention.
    Leys D; Balucani C; Cordonnier C
    Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    Diener HC
    Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MATCH results: implications for the internist.
    Lutsep HL
    Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study.
    Qureshi AI; Kirmani JF; Safdar A; Ahmed S; Sayed MA; Pande RU; Ferguson R; Hershey LA; Qazi KJ
    Pharmacotherapy; 2006 Apr; 26(4):493-8. PubMed ID: 16553507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
    Gorelick P; Sechenova O; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.